Clinical Trial Update: Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating boceprevir with pegylated interferon and ribavirin for HIV/HCV coinfection has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2016-05-10